Inventory analysts at StockNews.com assumed protection on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Score) in a report issued on Monday. The brokerage units a “promote” score on the inventory.
Navidea Biopharmaceuticals Inventory Efficiency
Navidea Biopharmaceuticals inventory opened at $0.24 on Monday. The corporate has a market cap of $7.29 million, a P/E ratio of -0.60 and a beta of 1.38. The agency’s 50-day transferring common is $0.44 and its 200-day transferring common is $0.69. Navidea Biopharmaceuticals has a 1 yr low of $0.23 and a 1 yr excessive of $1.83.
Navidea Biopharmaceuticals (NYSE:NAVB – Get Score) final issued its quarterly earnings information on Monday, August fifteenth. The corporate reported ($0.10) earnings per share for the quarter. The agency had income of $0.06 million through the quarter. Navidea Biopharmaceuticals had a adverse web margin of two,209.23% and a adverse return on fairness of 517.32%.
Navidea Biopharmaceuticals Firm Profile
Navidea Biopharmaceuticals, Inc., a biopharmaceutical firm, focuses on the event and commercialization of precision immunodiagnostic brokers and immunotherapeutics. It operates via two segments, Diagnostic Substances and Therapeutic Growth Applications. The corporate develops Manocept platform to focus on the CD206 mannose receptor expressed on activated macrophages for a spread of diagnostic modalities, together with single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, in addition to supply of therapeutic compounds that focus on macrophages, and immune-and inflammation-involved ailments.
Obtain Information & Scores for Navidea Biopharmaceuticals Every day – Enter your e mail deal with beneath to obtain a concise each day abstract of the newest information and analysts’ rankings for Navidea Biopharmaceuticals and associated corporations with MarketBeat.com’s FREE each day e mail publication.